The Protein Brewery Wins EU Approval for Fermotein Mycoprotein Six Years After Novel Foods Filing

Why It Matters

EU clearance validates the novel‑food pathway for whole‑cell protein, opening a fast‑growing market for sustainable ingredients and signaling regulatory readiness for future microbial foods.

Key Takeaways

• EU approves Fermotein, first novel mycelium ingredient
• Production 600 tons in 2027, >2,000 tons by 2029
• Powder format enables export to US, Singapore, Europe
• Less capital‑intensive, non‑sterile fermentation lowers costs
• Approval highlights need for faster EU novel‑food regulation

Pulse Analysis

The European Union’s novel‑food endorsement of Fermotein is a watershed moment for the emerging mycoprotein sector. After a six‑year review, the European Food Safety Authority’s positive opinion and the Standing Committee’s vote cleared a regulatory hurdle that many startups have feared. This approval not only legitimizes whole‑cell mycelium as a safe food ingredient but also establishes a precedent for future microbial proteins seeking entry into the EU’s stringent market, encouraging investors to consider the region’s untapped demand for sustainable protein.

From a commercial perspective, The Protein Brewery’s strategic choice to produce Fermotein as a dry powder rather than a wet biomass gives it a logistical edge. The powder’s neutral flavor, 50% complete protein, and high fiber content make it a versatile ingredient for fortified foods, beverages, and pet nutrition. With an initial 600‑ton supply slated for 2027 and a roadmap to exceed 2,000 tons by 2029, the company can meet commitments across Europe, the United States, and Singapore, leveraging its non‑sterile, lower‑capex fermentation process to stay cost‑competitive against wet‑mycoprotein rivals like Quorn.

Regulators, however, face pressure to accelerate the novel‑food pipeline. The Good Food Institute Europe highlighted the six‑year delay as a cautionary tale, urging the EU to boost EFSA capacity and provide clearer pre‑submission guidance. Faster approvals could unlock a broader wave of microbial‑protein innovations, from gas‑fermentation platforms to post‑biotic powders, expanding the sustainable protein landscape beyond meat analogues. As the sector matures, the Fermotein milestone may serve as a catalyst for harmonized standards that balance safety with the speed needed to meet global protein challenges.